Critical Survey: REGENXBIO (NASDAQ:RGNX) versus Vir Biotechnology (NASDAQ:VIR)Defense World · 2 days ago
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?Zacks Investment Research · Oct 15, 2026
Vir Biotechnology, Gilead Strike Deal for Novel Tumor TreatmentsBenzinga · Oct 14, 2026
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid TumorsBusiness Wire · Oct 14, 2026
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate CancerBusiness Wire · Oct 8, 2026
uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical ReviewDefense World · Oct 8, 2026Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $0.33 | $0.47 | Beat |
| May 6, 2026 | -$0.01 | -$0.85 | Miss |
| Feb 23, 2026 | -$0.42 | -$0.31 | Beat |
| Nov 5, 2025 | -$0.70 | -$1.17 | Miss |
| Aug 6, 2025 | -$0.72 | -$0.80 | Miss |
| May 7, 2025 | -$0.83 | -$0.88 | Miss |